Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 6 of 329 for:    Open Studies | "Macular Degeneration"

Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by Ora Bio Ltd..
Recruitment status was  Recruiting
Information provided by:
Ora Bio Ltd. Identifier:
First received: September 2, 2008
Last updated: June 7, 2009
Last verified: June 2009

This is s randomized, multi-center, double blind, 3 arm, phase I/II pilot study to evaluate the safety and efficacy of treatment with ORA102 combined with Avastin (Bevacizumab) versus Avastin alone, in patients with neo-vascular age related macular degeneration (AMD).

Condition Intervention Phase
Macular Degeneration
Drug: ORA102 and Avastin
Drug: Avastin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Multi-Center, Double Blind, 3 Arm, Phase I/II Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)

Resource links provided by NLM:

Further study details as provided by Ora Bio Ltd.:

Primary Outcome Measures:
  • The incidence and severity of ocular adverse events, including retinal detachment, increase in IOP, cataract, tearing of the retina, decrease in vision, RPE atrophy, and vitreous hemorrhage, will be evaluated. [ Time Frame: 32 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Central Retinal thickness and presence of intra/sub-retinal fluid observed by OCT at week 32 [ Time Frame: 32 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 96
Study Start Date: March 2009
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: ORA102 and Avastin
treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
Active Comparator: 2 Drug: ORA102 and Avastin
treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
Placebo Comparator: 3 Drug: Avastin
treatment with intravitreal injections of Avastin 1.25mg (0.05ml)


Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who have provided informed consent, including signing of the informed consent form
  • Subject who are able and willing to comply with the study protocol
  • Subject must have best corrected visual acuity ETDRS between 20/40 to 20/320 in the study eye
  • Subjects whose CNV lesion in the study eye contains more than 25% scarring and/or atrophy
  • Women must be post-menopausal 1 year or surgically sterilized. If not, negative serum pregnancy test required within 14 days of randomization

Exclusion Criteria:

  • Pregnant or lactating women
  • Patients with severe myocardial disease or coronary occlusion
  • Patients with severe personality disorder, suicidal risk or psychosis
  • Patients with previous history of CVA
  • Evidence for liver dysfunction - bilirubin level more than twice than upper limit of the normal value OR ALT/AST>1.5x upper limit of normal value
  • Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of the investigational drugs or puts the patients in high risk for treatment related complications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00745511

Contact: Yossi Israeli +972-26067006

Barzilai Medical Center Recruiting
Ashkelon, Israel
Carmel Medical Center Recruiting
Haifa, Israel
Hadassah Medical center Israel Recruiting
Jerusalem, Israel
Principal Investigator: Itay Chovers, MD         
Tel-Aviv Sourasky Medical Center Recruiting
Tel-Aviv, Israel
Ziv Medical Center Recruiting
Zefat, Israel
Sponsors and Collaborators
Ora Bio Ltd.
Principal Investigator: Itay Chovers, MD Hadassah Medical center
  More Information

No publications provided

Responsible Party: Yossi israeli, Ora Bio Ltd Identifier: NCT00745511     History of Changes
Other Study ID Numbers: OB-DAMD-01
Study First Received: September 2, 2008
Last Updated: June 7, 2009
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Ora Bio Ltd.:
macular degeneration
neo-vascular age related macular degeneration (AMD)

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Eye Diseases
Retinal Degeneration
Retinal Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 27, 2014